10:05 AM EST - Theratechnologies Inc. : said on Monday that the 52-week results from Phase 3 trials of its HIV lipohypertrophy treatment, tesamorelin, were consistent with those of a 26-week trial. The company said patients given tesamorelin (TH9507), designed to treat a disease that increases central fat accumulation in the body of HIV-infected patients, lost 18 percent of their visceral adipose tissue. Theratechnologies Inc.
shares T.TH are trading up $1.24 at $12.10.
